Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting.

摘要: The purpose of this study was to explore the budget impact dutasteride plus tamsulosin fixed-dose combination (DUT + TAM FDC) versus monotherapy, in treatment patients with benign prostatic hyperplasia (BPH) from perspective Greek healthcare insurance system. A Microsoft Excel-based model developed estimate financial consequences adopting DUT + TAM FDC within setting. model, compared six mutually exclusive health states two alternative options: current standard care and introduction market. used clinical inputs CombAT study; data on resource use associated management BPH Greece were derived expert panel, unit cost official reimbursement tariffs. payer taken into account. As patient distribution between public private sectors are not available scenarios investigated, considering whole eligible population each scenario. 4 year time horizon account included costs, number transurethral resections prostate (TURPs) acute urinary retention (AUR) episodes avoided. benefit market adoption DUT + TAM 1,758 TURPs 972 AUR avoided cumulatively a four period. increase total costs gradual system ranges €1.3 million first €5.8 fourth year, for sector, €1.2 €4.0 million, sector. This represents an 1.91% 7.94% sector 1.10% 3.29% during 4-year horizon. Budget analysis (BIA) results indicated that FDC, would overall disease, however providing better outcomes. drug acquisition is partly offset by reduction disease.